CancerCare Manitoba Research Institute was created in 2015 as a joint initiative of CancerCare Manitoba (CCMB) and the University of Manitoba (UM). It brings together basic discovery scientists from the former Manitoba Institute of Cell Biology (MICB) and clinical, health services, and patient experience scientists from UM and CCMB, all of whom research cancer and/or blood disorders.
The Research Institute is governed by an advisory board consisting of members appointed by CancerCare Manitoba and the University of Manitoba.
Dr. Neil Watkins is Director of the Research Institute.
Dr. Neil Watkins was appointed Director of the Research Institute in June 2019. His responsibilities include oversight of preclinical, translational and clinical research in cancer and blood disorders. This includes providing leadership and guidance to scientists, clinical researchers and stakeholders. He works with the University of Manitoba and CancerCare Manitoba Foundation in a strategic partnership with the goal of supporting excellence in research across the cancer journey.
Three major strategic directions were identified: developing multidisciplinary teams, enhancing infrastructure platforms and identifying research themes. Multidisciplinary teams will promote research excellence by building connections with the clinical and academic partners at CancerCare Manitoba (CCMB), Shared Health, Regional Health Authorities, and the University of Manitoba (UofM). Research platforms that support basic science, translational research, clinical trials, and epidemiology will be critical to support this multidisciplinary approach. Identification of research themes such as early detection, precision medicine, and health care innovation will maximize return on investment. Flexibility will be essential to adapt to the rapidly changing cancer research landscape.
It has been a very successful year for the Institute, with some outstanding achievements, new initiatives and opportunities. Read the full report for details.